{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:19:24Z","timestamp":1785442764097,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12974-019-1514-4","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T15:03:07Z","timestamp":1561042987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["A co-ultramicronized palmitoylethanolamide\/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis"],"prefix":"10.1186","volume":"16","author":[{"given":"Gabriella","family":"Contarini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Facci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Barbierato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Zusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"issue":"11","key":"1514_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","volume":"83","author":"P Browne","year":"2014","unstructured":"Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022\u20134.","journal-title":"Neurology."},{"issue":"10130","key":"1514_CR2","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622\u201336.","journal-title":"Lancet."},{"issue":"3","key":"1514_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1352458514522104","volume":"20","author":"L Schirmer","year":"2014","unstructured":"Schirmer L, Srivastava R, Hemmer B. To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Mult Scler. 2014;20(3):271\u20139.","journal-title":"Mult Scler."},{"issue":"9","key":"1514_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrd.2018.115","volume":"17","author":"V Di Marzo","year":"2018","unstructured":"Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):623\u201339.","journal-title":"Nat Rev Drug Discov."},{"issue":"Suppl 1","key":"1514_CR5","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.pain.2013.03.023","volume":"154","author":"S Maione","year":"2013","unstructured":"Maione S, Costa B, Di Marzo V. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. 2013;154(Suppl 1):S87\u201393.","journal-title":"Pain."},{"key":"1514_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.phrs.2014.05.006","volume":"86","author":"G Mattace Raso","year":"2014","unstructured":"Mattace Raso G, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease. Pharmacol Res. 2014;86:32\u201341.","journal-title":"Pharmacol Res"},{"issue":"4","key":"1514_CR7","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","volume":"96","author":"A Ligresti","year":"2016","unstructured":"Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016;96(4):1593\u2013659.","journal-title":"Physiol Rev."},{"key":"1514_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/bs.apha.2017.03.008","volume":"80","author":"M Pistis","year":"2017","unstructured":"Pistis M, O\u2019Sullivan SE. The role of nuclear hormone receptors in cannabinoid function. Adv Pharmacol. 2017;80:291\u2013328.","journal-title":"Adv Pharmacol."},{"issue":"2","key":"1514_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10787-013-0191-7","volume":"22","author":"SD Skaper","year":"2014","unstructured":"Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22(2):79\u201394.","journal-title":"Inflammopharmacology."},{"issue":"1","key":"1514_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.expneurol.2010.03.022","volume":"224","author":"HS Hansen","year":"2010","unstructured":"Hansen HS. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol. 2010;224(1):48\u201355.","journal-title":"Exp Neurol."},{"issue":"2","key":"1514_CR11","first-page":"11","volume":"19","author":"A Paladini","year":"2016","unstructured":"Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11\u201324.","journal-title":"Pain Physician."},{"key":"1514_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fphar.2018.00249","volume":"9","author":"S Petrosino","year":"2018","unstructured":"Petrosino S, Cordaro M, Verde R, Schiano Moriello A, Marcolongo G, Schievano C, Siracusa R, Piscitelli F, Peritore AF, Crupi R, Impellizzeri D, Esposito E, Cuzzocrea S, Di Marzo V. Oral ultramicronized palmitoylethanolamide: plasma and tissue levels and spinal anti-hyperalgesic effect. Front Pharmacol. 2018;9:249.","journal-title":"Front Pharmacol."},{"issue":"7","key":"1514_CR13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2174\/18715273113129990084","volume":"12","author":"R Crupi","year":"2013","unstructured":"Crupi R, Paterniti I, Ahmad A, Campolo M, Esposito E, Cuzzocrea S. Effects of palmitoylethanolamide and luteolin in an animal model of anxiety\/depression. CNS Neurol Disord Drug Targets. 2013;12(7):989\u20131001.","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"1514_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainresbull.2015.09.002","volume":"119","author":"SF Nabavi","year":"2015","unstructured":"Nabavi SF, Braidy N, Gortzi O, Sobarzo-Sanchez E, Daglia M, Skalicka-Wo\u017aniak K, Nabavi SM. Luteolin as an anti-inflammatory and neuroprotective agent: a brief review. Brain Res Bull. 2015;119(Pt A:1\u201311.","journal-title":"Brain Res Bull."},{"key":"1514_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.supflu.2018.07.020","volume":"143","author":"R Adami","year":"2019","unstructured":"Adami R, Liparoti S, Di Capua A, Scogliamiglio M, Reverchon E. Production of PEA composite microparticles with polyvinylpyrrolidone and luteolin using supercritical assisted atomization. J Supercrit Fluids. 2019;143:82\u20139.","journal-title":"J Supercrit Fluids."},{"key":"1514_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fphar.2016.00047","volume":"7","author":"R Crupi","year":"2016","unstructured":"Crupi R, Impellizzeri D, Bruschetta G, Cordaro M, Paterniti I, Siracusa R, Cuzzocrea S, Esposito E. Co-ultramicronized palmitoylethanolamide\/luteolin promotes neuronal regeneration after spinal cord injury. front pharmacol. 2016;7:47.","journal-title":"front pharmacol."},{"issue":"1","key":"1514_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1089\/neu.2014.3460","volume":"33","author":"M Cordaro","year":"2016","unstructured":"Cordaro M, Impellizzeri D, Paterniti I, Bruschetta G, Siracusa R, De Stefano D, Cuzzocrea S, Esposito E. Neuroprotective effects of co-UltraPEALut on secondary inflammatory process and autophagy involved in traumatic brain injury. J Neurotrauma. 2016;33(1):132\u201346.","journal-title":"J Neurotrauma."},{"issue":"9","key":"1514_CR18","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.2174\/1871527313666140806124322","volume":"13","author":"I Paterniti","year":"2014","unstructured":"Paterniti I, Cordaro M, Campolo M, Siracusa R, Cornelius C, Navarra M, Cuzzocrea S, Esposito E. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation. CNS Neurol Disord Drug Targets. 2014;13(9):1530\u201341.","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"1514_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s12975-015-0440-8","volume":"7","author":"C Caltagirone","year":"2016","unstructured":"Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G, et al. and Stroke Study Group Co-ultramicronized palmitoylethanolamide\/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res. 2016;7:54\u201369.","journal-title":"Transl Stroke Res."},{"key":"1514_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep16676","volume":"5","author":"M Barbierato","year":"2015","unstructured":"Barbierato M, Facci L, Marinelli C, Zusso M, Argentini C, Skaper SD, Giusti P. Co-ultramicronized palmitoylethanolamide\/luteolin promotes the maturation of oligodendrocyte precursor cells. Sci Rep. 2015;5:16676.","journal-title":"Sci Rep."},{"issue":"1","key":"1514_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12035-017-0722-0","volume":"55","author":"SD Skaper","year":"2018","unstructured":"Skaper SD, Barbierato M, Facci L, Borri M, Contarini G, Zusso M, Giusti P. Co-Ultramicronized palmitoylethanolamide\/luteolin facilitates the development of differentiating and undifferentiated rat oligodendrocyte progenitor cells. Mol Neurobiol. 2018;55(1):103\u201314.","journal-title":"Mol Neurobiol."},{"issue":"1","key":"1514_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12529-7","volume":"7","author":"M Barbierato","year":"2017","unstructured":"Barbierato M, Borri M, Facci L, Zusso M, Skaper SD, Giusti P. Expression and differential responsiveness of central nervous system glial cell populations to the acute phase protein serum amyloid A. Sci Rep. 2017;7(1):12158.","journal-title":"Sci Rep."},{"issue":"1-2","key":"1514_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0165-5728(98)00037-X","volume":"88","author":"G Ristori","year":"1998","unstructured":"Ristori G, Laurenti F, Stacchini P, Gasperini C, Buttinelli C, Pozzilli C, Salvetti M. Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. J Neuroimmunol. 1998;88(1-2):9\u201312.","journal-title":"J Neuroimmunol."},{"key":"1514_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/978-1-4939-7571-6_26","volume":"1727","author":"G Contarini","year":"2018","unstructured":"Contarini G, Giusti P, Skaper SD. Active induction of experimental autoimmune encephalomyelitis in C57BL\/6 mice. Methods Mol Biol. 2018;1727:353\u201360.","journal-title":"Methods Mol Biol."},{"key":"1514_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.neuroscience.2015.01.030","volume":"290","author":"A Rahimi","year":"2015","unstructured":"Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N. Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL\/6 mice. Neuroscience. 2015;290:279\u201387.","journal-title":"Neuroscience."},{"key":"1514_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fneur.2017.00233","volume":"8","author":"R Siracusa","year":"2017","unstructured":"Siracusa R, Impellizzeri D, Cordaro M, Crupi R, Esposito E, Petrosino S, Cuzzocrea S. Anti-inflammatory and neuroprotective effects of co-UltraPEALut in a mouse model of vascular dementia. Front Neurol. 2017;8:233.","journal-title":"Front Neurol."},{"issue":"11","key":"1514_CR27","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/bph.13580","volume":"174","author":"S Petrosino","year":"2017","unstructured":"Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174(11):1349\u201365.","journal-title":"Br J Pharmacol."},{"issue":"4","key":"1514_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12031-018-1094-2","volume":"65","author":"Z Ashaari","year":"2018","unstructured":"Ashaari Z, Hadjzadeh MA, Hassanzadeh G, Alizamir T, Yousefi B, Keshavarzi Z, Mokhtari T. The flavone luteolin improves central nervous system disorders by different mechanisms: a review. J Mol Neurosci. 2018;65(4):491\u2013506.","journal-title":"J Mol Neurosci."},{"issue":"2","key":"1514_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/bpa.12477","volume":"27","author":"W Barclay","year":"2017","unstructured":"Barclay W, Shinohara ML. Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Brain Pathol. 2017;27(2):213\u20139.","journal-title":"Brain Pathol."},{"issue":"11","key":"1514_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fnmol.2018.00320","volume":"4","author":"BZ Shao","year":"2018","unstructured":"Shao BZ, Cao Q, Liu C. Targeting NLRP3 inflammasome in the treatment of CNS diseases. Front Mol Neurosci. 2018;4(11):320.","journal-title":"Front Mol Neurosci."},{"issue":"2","key":"1514_CR31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4049\/jimmunol.0901363","volume":"183","author":"FG Bauernfeind","year":"2009","unstructured":"Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, Hornung V, Latz E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787\u201391.","journal-title":"J Immunol."},{"issue":"2","key":"1514_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0167-5699(94)90137-6","volume":"15","author":"H Baumann","year":"1994","unstructured":"Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15(2):74\u201380.","journal-title":"Immunol Today."},{"issue":"1","key":"1514_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12974-017-0969-4","volume":"14","author":"S Mardiguian","year":"2017","unstructured":"Mardiguian S, Ladds E, Turner R, Shepherd H, Campbell SJ, Anthony DC. The contribution of the acute phase response to the pathogenesis of relapse in chronic-relapsing experimental autoimmune encephalitis models of multiple sclerosis. J Neuroinflammation. 2017;14(1):196.","journal-title":"J Neuroinflammation."},{"key":"1514_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.brainres.2016.09.003","volume":"1654","author":"WY Jang","year":"2017","unstructured":"Jang WY, Lee BR, Jeong J, Sung Y, Choi M, Song P, Kim H, Jang S, Kim H, Joo KI, Lee JW, Choo YS, Kim E, Ryoo ZY. Overexpression of serum amyloid a 1 induces depressive-like behavior in mice. Brain Res. 2017;1654(Pt A:55\u201365.","journal-title":"Brain Res."},{"issue":"12","key":"1514_CR35","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1096\/fj.01-0133com","volume":"15","author":"PC Tucker","year":"2001","unstructured":"Tucker PC, Sack GH Jr. Expression of serum amyloid A genes in mouse brain: unprecedented response to inflammatory mediators. FASEB J. 2001;15(12):2241\u20136.","journal-title":"FASEB J."},{"issue":"12","key":"1514_CR36","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/002215549804601206","volume":"46","author":"S Urieli-Shoval","year":"1998","unstructured":"Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem. 1998;46(12):1377\u201384.","journal-title":"J Histochem Cytochem."},{"key":"1514_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3109\/13506120009146246","volume":"7","author":"TF Chung","year":"2000","unstructured":"Chung TF, Sipe JD, McKee A, Fine RE, Schreiber BM, Liang JS, Johnson RJ. Serum amyloid A in Alzheimer\u2019s disease brain is predominantly localized to myelin sheaths and axonal membrane. Amyloid. 2000;7:105\u201310.","journal-title":"Amyloid"},{"issue":"50","key":"1514_CR38","doi-asserted-by":"publisher","first-page":"18246","DOI":"10.1523\/JNEUROSCI.2473-12.2012","volume":"32","author":"JM Mart\u00ednez G\u00f3mez","year":"2012","unstructured":"Mart\u00ednez G\u00f3mez JM, Croxford JL, Yeo KP, Angeli V, Schwarz H, Gasser S. Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling. J Neurosci. 2012;32(50):18246\u201352.","journal-title":"J Neurosci."},{"issue":"1","key":"1514_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12974-016-0603-x","volume":"13","author":"E Kozela","year":"2016","unstructured":"Kozela E, Juknat A, Gao F, Kaushansky N, Coppola G, Vogel Z. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. J Neuroinflammation. 2016;13(1):136.","journal-title":"J Neuroinflammation."},{"issue":"3","key":"1514_CR40","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1750-3639.2002.tb00445.x","volume":"12","author":"H Zekki","year":"2002","unstructured":"Zekki H, Feinstein DL, Rivest S. The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS. Brain Pathol. 2002;12(3):308\u201319.","journal-title":"Brain Pathol."},{"key":"1514_CR41","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ejmech.2017.09.023","volume":"141","author":"ML Stama","year":"2017","unstructured":"Stama ML, \u015alusarczyk J, Lacivita E, Kirpotina LN, Schepetkin IA, Chamera K, Riganti C, Perrone R, Quinn MT, Basta-Kaim A, Leopoldo M. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation. Eur J Med Chem. 2017;141:703\u201320.","journal-title":"Eur J Med Chem."},{"issue":"14","key":"1514_CR42","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/bph.13847","volume":"174","author":"EL Hughes","year":"2017","unstructured":"Hughes EL, Becker F, Flower RJ, Buckingham JC, Gavins FNE. Mast cells mediate early neutrophil recruitment and exhibit anti-inflammatory properties via the formyl peptide receptor 2\/lipoxin A4 receptor. Br J Pharmacol. 2017;174(14):2393\u2013408.","journal-title":"Br J Pharmacol."},{"issue":"8","key":"1514_CR43","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.1007\/s12035-018-0889-z","volume":"55","author":"E Bisicchia","year":"2018","unstructured":"Bisicchia E, Sasso V, Catanzaro G, Leuti A, Besharat ZM, Chiacchiarini M, Molinari M, Ferretti E, Viscomi MT, Chiurchi\u00f9 V. Resolvin D1 halts remote neuroinflammation and improves functional recovery after focal brain damage via ALX\/FPR2 receptor-regulated microRNAs. Mol Neurobiol. 2018;55(8):6894\u2013905.","journal-title":"Mol Neurobiol."},{"key":"1514_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pharmthera.2016.06.011","volume":"166","author":"M Mecha","year":"2016","unstructured":"Mecha M, Carrillo-Salinas FJ, Feli\u00fa A, Mestre L, Guaza C. Microglia activation states and cannabinoid system: therapeutic implications. Pharmacol Ther. 2016;166:40\u201355.","journal-title":"Pharmacol Ther."},{"key":"1514_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pneurobio.2017.10.007","volume":"160","author":"V Chiurchi\u00f9","year":"2018","unstructured":"Chiurchi\u00f9 V, van der Stelt M, Centonze D, Maccarrone M. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog Neurobiol. 2018;160:82\u2013100.","journal-title":"Prog Neurobiol."},{"key":"1514_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lfs.2018.04.054","volume":"204","author":"M Toczek","year":"2018","unstructured":"Toczek M, Malinowska B. Enhanced endocannabinoid tone as a potential target of pharmacotherapy. Life Sci. 2018;204:20\u201345.","journal-title":"Life Sci."},{"issue":"3","key":"1514_CR47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/syn.1075","volume":"41","author":"F Berrendero","year":"2001","unstructured":"Berrendero F, S\u00e1nchez A, Cabranes A, Puerta C, Ramos JA, Garc\u00eda-Merino A, Fern\u00e1ndez-Ruiz J. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse. 2001;41(3):195\u2013202.","journal-title":"Synapse."},{"issue":"1","key":"1514_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.brainres.2006.06.001","volume":"1107","author":"A Cabranes","year":"2006","unstructured":"Cabranes A, Pryce G, Baker D, Fern\u00e1ndez-Ruiz J. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res. 2006;1107(1):199\u2013205.","journal-title":"Brain Res."}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-019-1514-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T23:10:53Z","timestamp":1592521853000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1514-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1514-4","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]},"assertion":[{"value":"31 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were conducted in compliance with EU guidelines for the care and use of laboratory animals and those of the Italian Ministry of Health (D.Lg. 26\/2014). The study was approved by the Institutional Review Board for Animal Research (Organismo Preposto al Benessere Animale, OPBA) of the University of Padua and by the Italian Ministry of Health (autorization number 65\/2017-PR).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}